HC Wainwright Issues Positive Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price hoisted by equities research analysts at HC Wainwright from $32.00 to $37.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 132.56% from the stock’s current price.

Several other equities research analysts have also recently commented on KURA. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. UBS Group started coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.67.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $15.91 on Thursday. The business has a 50 day moving average of $18.28 and a 200 day moving average of $19.82. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The company has a market cap of $1.24 billion, a PE ratio of -6.74 and a beta of 0.86. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of KURA. Avoro Capital Advisors LLC lifted its stake in shares of Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after buying an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC lifted its position in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Sofinnova Investments Inc. increased its holdings in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.